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Background: Hip fractures are recognized as one of the most
devastating injuries impacting older adults because of the complications
that follow. Mortality rates postsurgery can range from 14% to 58%
within one year of fracture. We aimed to identify factors associated with
increased risk of mortality within 24 months of a femoral neck fracture in
patients aged $50 years enrolled in the FAITH and HEALTH trials.
Methods: Two multivariable Cox proportional hazards regressions
were used to investigate potential prognostic factors that may be
associated with mortality within 90 days and 24 months of hip fracture.
Results: Ninety-one (4.1%) and 304 (13.5%) of 2247 participants
died within 90 days and 24 months of suffering a femoral neck
fracture, respectively. Older age (P, 0.001), lower body mass index
(P = 0.002), American Society of Anesthesiologists (ASA) class III/
IV/V (P = 0.004), use of an ambulatory aid before femoral neck
fracture (P , 0.001), and kidney disease (P , 0.001) were associ-
ated with a higher risk of mortality within 24 months of femoral neck
fracture. Older age (P = 0.03), lower body mass index (P = 0.02), use
of an ambulatory aid before femoral neck fracture (P , 0.001), and
having a comorbidity (P = 0.04) were associated with a higher risk of
mortality within 90 days of femoral neck fracture.
Conclusions: Our analysis found that factors that are indicative of
a poorer health status were associated with a higher risk of mortality
within 24 months of femoral neck fracture. We did not find a
difference in treatment methods (internal fixation vs. joint arthro-
plasty) on the risk of mortality.
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INTRODUCTION
Hip fractures have become a major public health
problem and are recognized as one of the most devastating
injuries impacting older adults because of the complications
that follow, which include chronic pain, diminished physical
health, quality of life, and premature death.1 As the global
population continues to age, the yearly incidence of hip
fractures has been projected to reach 6.26 million by 2050,
as compared to 1.66 million in 1990.1,2 Despite fractures of
the femoral neck typically being managed surgically, with
either internal fixation or arthroplasty methods, morbidity
and mortality rates remain high postsurgery.3–5 A systematic
review of 70 trials, published between 1981 and 2012, found
that mortality rates for femoral neck fracture patients were
similar over a 31-year period (;20%), whereas another
review reported that mortality rates can range from 14% to
58% within one year of fracture.3,6 In addition, the Fixation
using Alternative Implants for the Treatment of Hip frac-
tures (FAITH) and Hip fracture Evaluation with
ALternatives of Total hip arthroplasty versus
Hemiarthroplasty (HEALTH) trials have found similar high
mortality rates of 14.5% and 13.7%, respectively, within 24
months of hip fracture.7,8
Although the high mortality rate of hip fracture patients
is well documented, factors associated with mortality after hip
fracture have not been thoroughly examined in a large, global
patient population. Identifying which factors are associated
with mortality may assist surgeons in their treatment deci-
sions and, ultimately, enhance the care of hip fracture
patients. The objectives of this analysis were to identify
factors associated with an increased risk of mortality within
90 days and 24 months of a femoral neck fracture in patients




With a binary outcome, having fewer than 10 events for
each predictor variable can result in overfitted, unstable
models.9 Given that mortality was experienced within 24
months of femoral neck fracture in a total of 304 participants
from the FAITH (150 participants) and HEALTH (154 par-
ticipants) trials, the number of predictor variables included in
the first model was limited to 30 parameters. Because mor-
tality was experienced within 90 days of femoral neck frac-
ture in a total of 91 participants from the FAITH (40
participants) and HEALTH (51 participants) trials, the num-
ber of predictor variables included in the second model was
limited to 10 parameters. Based on biologic rationale, pre-
vious reports in the literature, and discussion with 2
orthopaedic surgeons, potential prognostic factors were
selected a priori from the study case report forms. Study
(FAITH vs. HEALTH) was included as one of the potential
prognostic factors to account for difference in intervention
status (surgical method of fracture management) between
the 2 studies. Because similar eligibility criteria were used
to enroll participants into the FAITH and HEALTH trials
and given that the survival experience was similar in both
trials, it was deemed appropriate to combine data from both
trials to evaluate our research questions.
Statistical Analyses
Complete-case analyses using multivariable Cox pro-
portional hazards regressions were used to investigate the
association between the selected baseline, fracture character-
istic, and surgical prognostic factors and the risk of mortality
within 90 days and 24 months of hip fracture in separate
models. Mortality of the FAITH and HEALTH trial partic-
ipants within 90 days and 24 months of hip fracture was
chosen as the dependent variable in each model, with
continent entered into the model as a stratification variable.
Participants who did not experience the event of mortality
were censored at 24 months (730 days) or time of last visit.
The analyses included continent to account for potential
differences in treatment practices between the geographic
locations that participants were recruited from. Selected
independent variables were entered into the multivariable
Cox proportional hazards regression models simultaneously.
Results were reported as adjusted hazard ratios (HR), 95%
confidence intervals (CIs), and P-values. All tests were 2-




One thousand six and 1241 participants enrolled in the
FAITH and HEALTH trials, respectively, totaling 2247
participants, had complete data for the independent variables
included in the mortality models. The majority of participants
were female (57.2%), the mean age was 75.3 years (SD 10.8),
and the mean body mass index (BMI) was 24.8 (SD 4.7).
Before injury, the majority of participants were independent
ambulators (77.0%), lived in a noninstitutionalized setting
(95.5%), did not use osteoporosis medications (92.6%), and
did not have any comorbidities, with the exception of high
blood pressure (56.7%). The typical femoral neck fracture
was displaced (69.7%), with a fracture line at the subcapital
level (59.5%), and assigned a type II Pauwels classification
(57.0%).11,12 Furthermore, the majority of participants had
either a Class I or Class II American Society of
Anesthesiologists (ASA) classification at baseline (54.4%).
The event of mortality was experienced in 304 [13.5% total;
150 (49.3%) from FAITH and 154 (50.7%) from HEALTH]
and 91 [4.1% total; 40 (44.0%) from FAITH and 51 (56.0%)
from HEALTH] participants within 24 months and 90 days of
femoral neck fracture, respectively (Table 1).
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TABLE 1. Baseline Participant Characteristics
Variable Death within 2 Years, N = 304 No Death Within 2 Years, N = 1943 Total, N = 2247
Age, mean (SD) y 80.6 (8.3) 74.5 (10.9) 75.3 (10.8)
Sex, n (%)
Female 155 (51.0) 1130 (58.2) 1285 (57.2)
Male 149 (49.0) 813 (41.8) 962 (42.8)
BMI, mean (SD) kg/m2 24.0 (4.9) 25.0 (4.6) 24.8 (4.7)
ASA classification, n (%)
Class I/II 94 (30.9) 1128 (58.1) 1222 (54.4)
Class III/IV/V 210 (69.1) 815 (41.9) 1025 (45.6)
Prefracture living setting, n (%)
Not institutionalized 276 (90.8) 1871 (96.3) 2147 (95.5)
Institutionalized 28 (9.2) 72 (3.7) 100 (4.5)
Prefracture functional status, n (%)
Independent ambulator 158 (52.0) 1572 (80.9) 1730 (77.0)
Using ambulatory aid 146 (48.0) 371 (19.1) 517 (23.0)
Study, n (%)
FAITH (internal fixation) 150 (49.3) 856 (44.1) 1006 (44.8)
HEALTH (joint replacement) 154 (50.7) 1087 (55.9) 1241 (55.2)
Baseline osteoporosis medication use,
n (%)
Yes 31 (10.2) 136 (7.0) 167 (7.4)
No 273 (89.8) 1807 (93.0) 2080 (92.6)
Heart disease, n (%)
Yes 149 (49.0) 574 (29.5) 723 (32.2)
No 155 (51.0) 1369 (70.5) 1524 (67.8)
High blood pressure, n (%)
Yes 209 (68.8) 1066 (54.9) 1275 (56.7)
No 95 (31.3) 877 (45.1) 972 (43.3)
Lung disease, n (%)
Yes 77 (25.3) 315 (16.2) 392 (17.4)
No 227 (74.7) 1628 (83.8) 1855 (82.6)
Diabetes, n (%)
Yes 72 (23.7) 323 (16.6) 395 (17.6)
No 232 (76.3) 1620 (83.4) 1852 (82.4)
Kidney disease, n (%)
Yes 64 (21.1) 140 (7.2) 204 (9.1)
No 240 (78.9) 1803 (92.8) 2043 (90.9)
Depression, n (%)
Yes 47 (15.5) 242 (12.5) 289 (12.9)
No 257 (84.5) 1701 (87.5) 1958 (87.1)
Fracture displacement, n (%)
Undisplaced 124 (40.8) 556 (28.6) 680 (30.3)
Displaced 180 (59.2) 1387 (71.4) 1567 (69.7)
Level of the fracture line, n (%)
Subcapital 212 (69.7) 1126 (58.0) 1338 (59.5)
Midcervical 73 (24.0) 704 (36.2) 777 (34.6)
Basal 19 (6.3) 113 (5.8) 132 (5.9)
Pauwels classification, n (%)
Type I 50 (16.4) 237 (12.2) 287 (12.8)
Type II 184 (60.5) 1097 (56.5) 1281 (57.0)
Type III 70 (23.0) 609 (31.3) 679 (30.2)
Time from injury to surgery, mean
(SD) hours
58.1 (69.7) 50.8 (74.2) 51.8 (73.7)
Length of surgery, mean (SD)
minutes
71.1 (40.4) 75.3 (37.8) 74.7 (38.2)
(continued on next page )
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Predictors of 24-Month Mortality
Older age (HR 1.42 for every 10-year increase, 95% CI
1.22–1.65; P , 0.001), lower BMI (HR 1.23 for every 5-
point decrease, 95% CI 1.08–1.39; P = 0.002), American
Society of Anesthesiologists (ASA) class III/IV/V (HR 1.53
vs. class I/II, 95% CI 1.14–2.04; P = 0.004), use of an ambu-
latory aid before femoral neck fracture (HR 2.10 vs. ambulat-
ing independently, 95% CI 1.63–2.71; P , 0.001), and
kidney disease (HR 2.14, 95% CI 1.60–2.86; P , 0.001)
were associated with a higher risk of mortality within 24
months of femoral neck fracture (Table 2). We did not find
a difference in treatment methods (internal fixation vs. joint
arthroplasty) in the risk of mortality. In addition, no other
factors were significantly associated with mortality (P .
0.05).
Predictors of 90-Day Mortality
Ninety-nine (4.1%) of 2247 participants died within 90
days of femoral neck fracture. Older age (HR 1.34 for every 10-
year increase, 95% CI 1.04–1.73; P = 0.03), lower BMI (HR
1.33 for every 5-point decrease, 95% CI 1.04–1.70; P = 0.02),
use of an ambulatory aid before femoral neck fracture (HR 4.39
vs. ambulating independently, 95% CI 2.74–7.02; P , 0.001),
and having a comorbidity (HR 2.27, 95% CI 1.02–5.04; P =
0.04) were associated with a higher risk of mortality within 90
days of femoral neck fracture (Table 3). No other factors were
significantly associated with mortality (P . 0.05).
DISCUSSSION
Using data from the FAITH and HEALTH trials, we
investigated which factors are associated with mortality
within 90 days and 24 months of femoral neck fracture.
Older age, lower BMI, ASA class III/IV/V, use of an
ambulatory aid before femoral neck fracture, and kidney
disease were factors found to be associated with a higher risk
of mortality within 24 months of femoral neck fracture in this
analysis. Older age, lower BMI, use of an ambulatory aid
before femoral neck fracture, and having a comorbidity were
factors found to be associated with a higher risk of mortality
within 90 days of femoral neck fracture in this analysis.
Overall, the majority of the findings from our analysis support
the existing literature concerning predictive variables of
mortality after hip fracture.6,13–18
Increasing age was a factor found to be associated with
a higher risk of 1-, 2-, 3-, 5-, and 10-year mortality across
several previously completed studies.6,13–22 Other studies
have identified kidney disease, including renal failure, which
is the final stage of chronic kidney disease, to be an essential
predictor of mortality following hip fracture.14,20,23,24
Although we did control for ASA grade in our analysis,
patients with chronic kidney disease usually have more co-
morbidities and more postoperative complications, which are
highly likely to contribute to mortality within 90 days of hip
fracture surgery.23,24
Lower BMI being predictive of mortality within 24
months of hip fracture was another finding from our analysis
that supports the current published literature.18,25,26 In partic-
ular, one study reported that patients with a BMI .26 had a
lower mortality rate than those with BMI ,22 (odds ratio 2.6
for the 1-year survival, 95% CI 1.20–5.50; P = 0.006).25
Similarly, another study found that compared to participants
of normal weight, mortality in overweight (HR 0.74, 95% CI
0.62–0.88; P = 0.001) and obese (HR 0.74, 95% CI 0.60–
0.91; P = 0.004) participants was significantly lower after
sustaining a hip fracture.26 Although the observation of high-
er mortality in individuals with a lower BMI is consistent
among the published literature, further research is still
required to understand the reasons for reduced mortality in
obese and overweight participants when compared to those of
normal weight.26 There is evidence suggesting that poor
nutritional status is linked to increased mortality in hip frac-
ture patients, which may explain why underweight partici-
pants with a lower BMI are at a higher risk of mortality.22,27
The impact of time from injury to hip surgery has been
a topic of discussion among orthopaedic surgeons. In our
TABLE 1. (Continued ) Baseline Participant Characteristics
Variable Death within 2 Years, N = 304 No Death Within 2 Years, N = 1943 Total, N = 2247
Type of anesthesia, n (%)
General 139 (45.7) 1042 (53.6) 1181 (52.6)
Regional 165 (54.3) 901 (46.4) 1066 (47.4)
Intraoperative blood loss, mean
(SD), mL
203.0 (200.5) 207.4 (180.4) 206.8 (183.2)
Postoperative thromboprophylaxis,
n (%)
Yes 301 (99.0) 1932 (99.4) 2233 (99.4)
No 3 (1.0) 11 (0.6) 14 (0.6)
Majority of procedure performed by,
n (%)
Surgeon 187 (61.5) 1188 (61.1) 1375 (61.2)
Resident 99 (32.6) 641 (33.0) 740 (32.9)
Fellow 18 (5.9) 114 (5.9) 132 (5.9)
ASA, American Society of Anesthesiologists; BMI, body mass index; SD, standard devation.
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analysis, the mean time from injury to surgery was 57.9 hours
(SD 215.4 hours) and not found to be significantly associated
with mortality within 24 months (HR 1.00, 95% CI 1.00–
1.00; P = 0.86) nor within 90 days (HR 1.00, 95% CI
0.998–1.003; P = 0.69) of fracture. The recently completed
HIP ATTACK (The Hip Fracture Accelerated Surgical
Treatment and Care Track) trial aimed to definitively answer
this particular question by examining whether accelerated
care (surgery within 6 hours of hip fracture diagnosis) versus
standard care (surgery within 24 hours) could reduce mortal-
ity and major complications in hip fracture patients aged 45
years or older.28 The trial did not find a reduction in mortality
at 30 and 90 days when surgery was conducted within 6
hours, as well as found no difference between the surgery
groups on major complications occurring within 90 days.28
However, it has been proposed that earlier surgery may
shorten the period of immobility, which may improve func-
tional outcomes, lessen costs and, ultimately, reduce morbid-
ity and mortality in the long run.
Several studies found that a high ASA classification as
well as ambulating with an assistive device before hip fracture
was predictive of mortality.13,18,21,22,27 It has been hypothe-
sized that the use of an ambulatory aid may lead to higher
mortality rates because it delays the patient’s ability to imme-
diately bear weight after hip fracture surgery or may be a
surrogate for frailty.29
Despite our findings indicating otherwise, there have
been studies published reporting that being institutionalized
before femoral neck fracture is associated with a higher risk
of mortality.20,30 In a retrospective cohort study of 3992
patients older than 45 years having an osteoporotic hip frac-
ture, institutionalization before injury occurrence (incidence
rate ratio 1.48, 95% CI 1.36–1.60; P , 0.05) was associated
with a higher risk of mortality within 5 years of injury.20
In our analysis, we found that treatment method
(internal fixation in the FAITH trial vs. joint arthroplasty in
the HEALTH trial) was not significantly associated with
mortality (P = 0.36) overall within 24 months nor within 90
days (P = 0.62) of fracture. Numerous published studies sup-
port our finding that there is no overall difference in mortality
TABLE 2. Factors Associated With 24-Month Mortality
(n = 2247; 304 Events)
Independent Variable HR (95% CI) P
Age (10-y increase) 1.42 (1.22–1.65) ,0.001
BMI (5-point decrease) 1.23 (1.08–1.39) 0.002
ASA classification
Class III/IV/V vs. Class I/II 1.53 (1.14–2.04) 0.004
Prefracture functional status




Yes vs. no 2.14 (1.60–2.86) ,0.001
Sex






FAITH (internal fixation) vs.
HEALTH (joint replacement)
0.79 (0.48–1.31) 0.36
Baseline osteoporosis medication use
Yes vs. no 1.02 (0.69–1.52) 0.91
Heart disease
Yes vs. no 1.14 (0.88–1.47) 0.33
High blood pressure
Yes vs. no 1.02 (0.79–1.33) 0.86
Lung disease
Yes vs. no 1.26 (0.96–1.66) 0.10
Diabetes
Yes vs. no 1.22 (0.92–1.62) 0.17
Depression
Yes vs. no 0.98 (0.70–1.36) 0.89
Fracture displacement
Displaced vs. undisplaced 0.75 (0.48–1.18) 0.21
Level of the fracture line
Midcervical vs. subcapital 0.85 (0.64–1.12)
Basal vs. subcapital 1.48 (0.90–2.41) Overall: 0.10
Pauwels classification
Type I vs. type III 1.15 (0.77–1.72)
Type II vs. type III 1.08 (0.80–1.46) Overall: 0.79
Time from injury to surgery (h) 1.001 (0.99–1.002) 0.33
Length of surgery (mins) 1.001 (0.99–1.004) 0.67
Type of anesthesia
General vs. Regional 1.04 (0.79–1.36) 0.79
Intraoperative blood loss (mL) 1.00 (1.00–1.001) 0.21
Postoperative thromboprophylaxis
Yes vs. no 0.58 (0.14–2.40) 0.45
Majority of procedure performed by
Resident vs. surgeon 0.98 (0.76–1.27)
Fellow vs. surgeon 1.05 (0.64–1.72) Overall: 0.97
ASA, American Society of Anesthesiologists; BMI, body mass index.
TABLE 3. Factors Associated With 90-Day Mortality (n = 2247;
91 Events)
Independent Variable HR (95% CI) P
Age (10-y increase) 1.34 (1.04–1.73) 0.03
BMI (5-point decrease) 1.33 (1.04–1.70) 0.02
Prefracture functional status




Yes vs. No 2.27 (1.02–5.04) 0.04
ASA classification
Class III/IV/V vs. Class I/II 1.44 (0.87–2.38) 0.15
Study
FAITH (internal fixation) vs.
HEALTH (joint replacement)
0.88 (0.53–1.46) 0.62
Time from injury to surgery (hours) 1.00 (0.998–1.003) 0.69
Length of surgery (minutes) 0.99 (0.992–1.004) 0.51
Type of anesthesia
General vs. Regional 0.88 (0.55–1.41) 0.58
ASA, American Society of Anesthesiologists; BMI, body mass index.
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between patients treated with arthroplasty versus internal fix-
ation.27,31–34 However, some published literature has sug-
gested trends of internal fixation favoring mortality
reduction.27,34,35 A prospective multicenter study of 697
patients aged over 80 years, presenting with a fracture of
the upper femur, treated with either internal fixation or arthro-
plasty found that in their univariate analysis, mortality was
higher with arthroplasty (25%) than with internal fixation
(17%; P = 0.002), but that the effect no longer existed in their
multivariate analysis (P. 0.05).27 Bhandari et al35 conducted
a meta-analysis to determine the effect of arthroplasty (hemi-
arthroplasty, bipolar arthroplasty, and total hip arthroplasty)
versus internal fixation (with a fixed-angle screw and plate or
with multiple screws) on rate of mortality in patients aged 65
years or older with a displaced femoral neck fracture. The
authors found a trend toward an increase in the relative risk
of death in the first 4 months and at one year after arthroplasty
compared with internal fixation. Another meta-analysis of
elderly patients with displaced femoral neck fractures com-
pared the effect of arthroplasty versus internal fixation on
various clinical outcomes and found that, overall, there was
increased postoperative risk for mortality with arthroplasty as
compared to internal fixation, but that there was no statisti-
cally significant difference between the 2 groups at the dif-
ferent follow-up times.34
The primary strength of this analysis is the preplanned
analysis of a large number of well characterized patients from
over 130 clinical sites across 12 countries that were included
when examining the research questions. Such a large and diverse
sample size increases the external validity and generalizability of
the research findings from this analysis. Another strength is that
we focused on femoral neck fractures, whereas most published
studies on this topic have combined all hip fracture types
together. However, not being able to include all participants
from the FAITH and HEALTH trials in this analysis as a result
of missing data was a limitation. In addition, because only those
variables that were collected as part of the FAITH and HEALTH
trials could be used in the analysis, it may be possible that not all
factors associated with mortality were captured. Both trials also
had strict exclusion criteria that may have resulted in healthier
patients being enrolled. For example, patients must have been
ambulatory before the fracture (although they may have used an
aid such as a cane or walker) and had no history of frank
dementia to be included. Given the possibility that healthier
patients were enrolled in both trials, this may explain, in part, a
lower 24-month mortality rate of 13.5%, as compared to higher
rates in the literature.
In conclusion, given the major public health problem
surrounding femoral neck fractures in older adults, it is
necessary to gain a further understanding of which patients
are at risk for mortality in order for surgeons to be able to
provide their patients with an accurate prognosis following
injury and to develop intervention strategies. Our analysis
found that factors that are indicative of a poorer health status,
such as older age, lower BMI, worse ASA class, use of an
ambulatory aid, and kidney disease, were associated with a
higher risk of mortality. We did not find treatment methods
(internal fixation vs. joint arthroplasty) to be overall signif-
icantly associated with mortality.
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